EMA Withdrawn: Mycapssa (octreotide acetate) — Amryt Pharmaceuticals DAC

View source ↗

Summary

The EMA has withdrawn the marketing authorization for Mycapssa (octreotide acetate) for acromegaly.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acromegaly

Drugs mentioned

• MYCAPSSA (OCTREOTIDE)

Snippet

Status: Withdrawn. Therapeutic area: Acromegaly. MAH: Amryt Pharmaceuticals DAC. Decision date: 02/12/2022